Oragenics Inc (OGEN) stock
OGENNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.20−0.15 (-42.59%)
Close on Nov 13, 2026Market cap $906.90KP/E –Yield –
Oragenics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Oragenics's EPS for the twelve months ending Sep 30, 2024 was -$32.21. For fiscal 2025 it was -$4.56. The highest annual figure on record is -$4.56 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.56 | – |
| FY2024 | Dec 31, 2024 | -$47.88 | – |
| FY2023 | Dec 31, 2023 | -$9.18 | – |
| FY2022 | Dec 31, 2022 | -$7.11 | – |
| FY2021 | Dec 31, 2021 | -$8.12 | – |
| FY2020 | Dec 31, 2020 | -$27.26 | – |
| FY2019 | Dec 31, 2019 | -$21.46 | – |
| FY2018 | Dec 31, 2018 | -$50.46 | – |
| FY2017 | Dec 31, 2017 | -$79.46 | – |
| FY2016 | Dec 31, 2016 | -$91.06 | – |
| FY2015 | Dec 31, 2015 | -$185.60 | – |
| FY2014 | Dec 31, 2014 | -$92.80 | – |
| FY2013 | Dec 31, 2013 | -$324.80 | – |
| FY2012 | Dec 31, 2012 | -$429.20 | – |
| FY2011 | Dec 31, 2011 | -$777.20 | – |
| FY2010 | Dec 31, 2010 | -$823.60 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.58 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.57 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.51 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.96 | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.10 | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.65 | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.32 | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.27 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.70 | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.92 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.85 | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.51 | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.41 | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.01 | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.99 | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.85 | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.29 | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.14 | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.32 | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.74 | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.90 | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.32 | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.64 | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.92 | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.38 | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.64 | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.64 | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.80 | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.38 | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.22 | – |
| Q3 FY2018 | Sep 30, 2018 | -$20.30 | – |
| Q2 FY2018 | Jun 30, 2018 | -$22.04 | – |
| Q1 FY2018 | Mar 31, 2018 | -$24.36 | – |
| Q4 FY2017 | Dec 31, 2017 | -$17.18 | – |
| Q3 FY2017 | Sep 30, 2017 | -$24.36 | – |
| Q2 FY2017 | Jun 30, 2017 | -$14.50 | – |
| Q1 FY2017 | Mar 31, 2017 | -$23.20 | – |
| Q4 FY2016 | Dec 31, 2016 | -$31.53 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?